Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
5.18
+0.19 (3.81%)
At close: Apr 22, 2026, 4:00 PM EDT
5.08
-0.10 (-1.93%)
After-hours: Apr 22, 2026, 6:16 PM EDT
Atara Biotherapeutics Revenue
In the year 2025, Atara Biotherapeutics had annual revenue of $120.77M, down -6.33%. Atara Biotherapeutics had revenue of $1.60M in the quarter ending December 31, 2025, a decrease of -95.13%.
Revenue (ttm)
$120.77M
Revenue Growth
-6.33%
P/S Ratio
0.35
Revenue / Employee
$8,626,571
Employees
14
Market Cap
42.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 120.77M | -8.17M | -6.33% |
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Aligos Therapeutics | 2.19M |
| Werewolf Therapeutics | 1.14M |
| RenovoRx | 1.12M |
| Rallybio | 858.00K |
| Hyperion DeFi | 813.46K |
| Actinium Pharmaceuticals | 90.00K |
ATRA News
- 6 days ago - ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses - PRNewsWire
- 15 days ago - ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role - GlobeNewsWire
- 5 weeks ago - Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - Business Wire
- 5 weeks ago - Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Business Wire
- 2 months ago - Atara Biotherapeutics Provides a Business Update - Business Wire
- 3 months ago - Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire
- 5 months ago - Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire
- 6 months ago - Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire